Delivery Order SPE2DB24D2106-SPE2DB25FAUAF
Award Date
11/13/24
Potential Completion Date
11/14/24
Potential Value
$7.8K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 contract is for the delivery of STELARA 90 MG/ML SYRINGE with a period of performance through March 20, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a performance period ending on April 22, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a completion date of April 25, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized medication, with a performance period through March 31, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $64,999.80 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product, with a completion date of July 17, 2025. DMS Pharmaceutical Group has a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The $8,220.68 contract provides for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a completion date of April 15, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a ceiling value of $8,220.68 and a period of performance through March 26, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,538.62 award is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical needs of the Department of Defense (DoD). This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $57,544.76, is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group Inc., valued at $499,999,999, which allows the DLA to issue delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,317.85 award is for the supply of STELARA 90 mg/ml syringes, with a period of performance through June 25, 2024. It is issued under an existing $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, which allows the agency to place delivery orders for a wide range of...